BioSpace News Archive

STRATA Skin Sciences, Inc. announced financial results for the fourth quarter and full-year ended December 31, 2023.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.

Castle Biosciences, Inc. announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

American Shared Hospital Services announced financial results for the fourth quarter ended December 31, 2023.

BioSyent Inc. announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.

Voom™ Medical Devices, Inc. (“Voom”), a revolutionary medical device company transforming the landscape of minimally invasive bunion surgery (MIBS) education, is thrilled to announce the official launch of its new one-on-one surgeon training program for the Bunionplasty® 360 Bunion Repair™ procedure.